Using current techniques, Alzheimer’s disease, the most frequent cause of dementia, can only be detected once the typical plaques have formed in the brain. At this point, therapy seems no longer possible. However, the first changes caused by Alzheimer’s take place on the protein level up to 20 years sooner. A two-tier method developed at Ruhr-Universität Bochum (RUB) can help detect the disease at a much earlier stage. The researchers from Bochum published their report in the March 2019 edition of the journal “Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring”.
“This has paved the way for early-stage therapy approaches, where the as yet inefficient drugs on which we had pinned our hopes may prove effective,” says Professor Klaus Gerwert from the Department of Biophysics at RUB.
Protein folds incorrectly
In Alzheimer’s patients, the amyloid beta protein folds incorrectly due to pathological changes long before the first symptoms occur. A team of researchers headed by Klaus Gerwert successfully diagnosed this misfolding using a simple blood test; as a result, the disease can be detected approximately eight years before the first clinical symptoms occur. The test wasn’t suitable for clinical applications however: it did detect 71 per cent of Alzheimer’s cases in symptomless stages, but at the same time provided false positive diagnoses for nine per cent of the study participants. In order to increase the number of correctly identified Alzheimer’s cases and to reduce the number of false positive diagnoses, the researchers poured a lot of time and effort into optimising the test.
As a result, they have now introduced the two-tier diagnostic method. To this end, they use the original blood test to identify high-risk individuals. Subsequently, they add a dementia-specific biomarker, namely tau protein, to run further tests with those test participants whose Alzheimer’s diagnosis was positive in the first step. If both biomarkers show a positive result, there is a high likelihood of Alzheimer’s disease. “Through the combination of both analyses, 87 of 100 Alzheimer’s patients were correctly identified in our study,” summarises Klaus Gerwert. “And we reduced the number of false positive diagnoses in healthy subjects to 3 of 100. The second analysis is carried out in cerebrospinal fluid that is extracted from the spinal cord.
“Now, new clinical studies with test participants in very early stages of the disease can be launched,” points out Gerwert. He is hoping that the existing therapeutic antibodies will still have an effect. “Recently, two major promising studies have failed, especially Crenezumab and Aducanumab – not least because it had probably already been too late by the time therapy was taken up. The new test opens up a new therapy window.”
“Once amyloid plaques have formed, it seems that the disease can no longer be treated,” says Dr. Andreas Nabers, head of the research group and co-developer of the Alzheimer’s sensor. “If our attempts to arrest the progression of Alzheimer’s fail, it will put a lot of strain on our society.”
Sensor test is simple and robust
The blood test has been upgraded to a fully automated process at the RUB Department of Biophysics. “The sensor is easy to use, robust when it comes to fluctuation in concentration of biomarkers, and standardised,” explains Andreas Nabers. “We are now conducting in-depth research to detect the second biomarker, namely tau protein, in the blood, in order to supply a solely blood-based test in future,” concludes Klaus Gerwert.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Air-Pollution Linked To Alzheimer's Disease In Older Womenon November 27, 2020 at 3:00 pm
USC Researchers found that older women who live in areas with high levels of air pollution are more likely to suffer brain shrinkage.
- Cassava up 3% after USAN modifies lead drug candidate's chemical name to simufilam for Alzheimer’s diseaseon November 27, 2020 at 10:48 am
(NASDAQ:SAVA) says that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company’s lead drug candidate to 'simufilam' from ...
- Connecting Financial Literacy to Cognitive Health and Alzheimer'son November 27, 2020 at 5:06 am
Having trouble managing your finances, research has shown, can be an early sign of cognitive difficulty and even dementia. But two fascinating recent studies suggest how important it can be to your ...
- Readers respond: Let Alzheimer’s patients use lawon November 27, 2020 at 4:30 am
In most cases, even highly trained physicians cannot determine if an Alzheimer’s patient will die within six months. And people about to die from Alzheimer’s disease are not eligible to use the law ...
- 10 simple tips that will help prevent Alzheimer's disease and dementiaon November 27, 2020 at 3:02 am
In fact, 44% of 1,200 adults surveyed by the Marist Institute for Public Opinion were more scared of getting Alzheimer's disease than cancer, stroke, heart disease or diabetes. What you may not ...
- Anxiety independently linked to faster onset of Alzheimer's diseaseon November 26, 2020 at 8:38 pm
Feelings of apprehension and fear are often observed in those suffering mild cognitive impairment (MCI), and previous research has suggested that anxiety could be an early indicator for Alzheimer's ...
- CRISPR gene editing of brain cells might prevent Alzheimer's diseaseon November 26, 2020 at 12:11 pm
CRISPR gene editing could be used to introduce a rare gene variant that greatly reduces the risk of Alzheimer's, but it has only been tried in a dish so far ...
- Global Alzheimer's Disease Drug Market 2020 Key Stakeholders, Growth Opportunities, Value Chain and Sales Channels Analysis 2025on November 26, 2020 at 2:49 am
Global Alzheimer's Disease Drug Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 reveals the overview of the global industry, encompassing the latest industry data and ...
- PostEra and NeuroLucent collaborate on identifying small-molecule therapeutics for Alzheimer’s diseaseon November 25, 2020 at 12:31 pm
The failure of late-stage clinical trials to uncover effective therapies for Alzheimer’s disease has underscored the need to explore novel therapeutic approaches. NeuroLucent is developing novel small ...
- Central trafficking compartment in neurons malfunctions in majority of Alzheimer's patientson November 25, 2020 at 11:02 am
Decades before the first symptoms of Alzheimer's appear, the brain's neurons start secreting tau proteins, one of the first changes known to occur in the course of the disease.
via Bing News